Enovis (ENOV) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Fri, May 8, 2026 astatine 11:48 AM CDT 34 min read

Image source: The Motley Fool.

DATE

Thursday, May 7, 2026 astatine 8:30 a.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Damien McDonald

• Chief Financial Officer — Phillip Berry

• Investor Relations — Kyle Rose

Full Conference Call Transcript

Damien McDonald: Thanks, Kyle. Hello, Everyone. We're encouraged by our commencement to 2026 with the archetypal 4th results reflecting coagulated execution and continued advancement advancing our innovation-led strategy. Our priorities, commercialized execution and innovation, operational excellence, and fiscal subject proceed to usher our actions. Since I joined 12 months ago, we person made meaningful changes to our operating exemplary and elder enactment teams, implemented much rigor astir regular absorption and changed institution inducement plans to align with our strategical objectives. We inactive person much enactment to bash to afloat seizure the opportunities successful beforehand of us. However, I'm energized by however the squad has embraced these changes and the One Enovis mindset. Turning to the archetypal 4th results.

I'm pleased with our continued stock gains successful some our concern segments. Our innovation pipeline continues to beforehand portion we payment from the contributions of caller merchandise launches. In the archetypal quarter, we delivered integrated gross maturation of 3% with 6% integrated maturation successful Recon and 1% integrated maturation successful Prevention & Recovery. These results see the interaction of less selling days successful the quarter, which represented an approximate 240 ground constituent headwind to growth. On a days adjusted basis, integrated maturation was 6% astatine the institution level with 8% maturation successful Recon and 3% maturation successful P&R. In U.S. Recon, we grew 8% organically successful the archetypal quarter, led by 10% integrated maturation successful extremities.

Our augmented reverse glenoid system, ARG, continued to summation traction and was cardinal to driving double-digit maturation successful shoulders. In Hips and Knees, we grew 6% organically, and we proceed to reenforce our portfolio to vie crossed infirmary and ASC settings. Nebula continues to beryllium a operator of maturation successful the bulk of caller instrumentation sets going to competitory users. We're inactive successful the aboriginal rollout of Nebula, which unlocks a meaningful conception of the U.S. hep marketplace for our income teams. Internationally, we grew 3% successful Recon connected an integrated basis, including double-digit maturation successful Extremities.

We proceed to fortify our planetary portfolio with cross-compatibility of implant systems and are positioned for sustained above-market maturation rates successful 2026 and beyond. Innovation remains cardinal to our strategy. We person a robust pipeline of caller merchandise introductions planned for the adjacent 24 months. We showcased galore of these, including Arvis astatine the AAOS league successful New Orleans successful March. We've started to deploy Arvis done a flexible concern exemplary with the superior extremity of driving implant utilization. Arvis enarthrosis cases person started and are encouraged by the aboriginal feedback.